Addex Therapeutics Ltd. | Mutual Funds
Mutual Funds that own Addex Therapeutics Ltd.
Herculis Partners Aries Fund
306,903
1.07%
0
14.57%
07/31/2018
Herculis Partners Taurus Fund
280,000
0.98%
250,000
6.7%
03/29/2018
CSIF Switzerland Total Market Index
170,988
0.6%
-4,412
0.01%
05/31/2018
APO Medical Opportunities
104,345
0.37%
104,345
0.05%
03/31/2018
CSIF Switzerland Small & Mid Cap Index
64,146
0.23%
-1,768
0.03%
05/31/2018
ZKB - CIF Small & Mid Cap Index
36,157
0.13%
0
0.01%
07/31/2018
APO Medical Opportunities Institutionell
27,000
0.1%
0
0.04%
06/29/2018
27,000
0.1%
0
0%
12/29/2017
UBS (CH) Institutional Fund - Equities Switzerland Passive All
26,000
0.09%
0
0%
12/29/2017
iShares Core SPI (CH)
25,343
0.09%
0
0.01%
09/07/2018
| Address |
12, Chemin des Aulx
Geneva Geneve (Geneva) 1228
Switzerland
|
|
Employees
|
- |
| Website |
http://www.addextherapeutics.com |
| Updated |
07/08/2019 |
| Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland. |
